Printer Friendly

Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors.

IMMUNOHISTOCHEMICAL MARKERS FOR CELLULAR DIFFERENTIATION OF SALIVARY GLAND TUMORS

There are 34 benign and malignant salivary gland epithelial tumors according to the 2005 third histologic classification of the World Health Organization. (1) These tumors can show diverse morphology and overlapping histologic features. Although accurate diagnoses can be made on the basis of hematoxylin-eosin sections of most salivary gland tumors, immunohistochemistry can provide a powerful adjunct tool for pathologists to identify the cellular differentiation and assign correct classifications in difficult tumor cases.

The salivary glands include 3 major pairs of salivary glands (parotid, submandibular, and sublingual) and many minor salivary glands, which can be located throughout the upper respiratory tract. The glands are composed of acini (serous, mucinous, and mixed) and ducts (intercalated, striated, and excretory). The acini and intercalated duct are surrounded by myoepithelial cells. The striated duct and excretory duct are surrounded by basal cells. Most salivary gland tumors originate from acinar/ductal epithelial cells (luminal cells) and/or myoepithelial/basal cells (abluminal cells). Monophasic tumors have only 1 cellular component, either originating from acinar/ductal epithelial cells or from myoepithelial/basal cells. These include tumors such as myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. The tumors originating from both acinar/ductal epithelial cells and myoepithelial/basal cells are designated biphasic tumors, and this category includes tumors such as pleomorphic adenoma, epithelial myoepithelial carcinoma, and adenoid cystic carcinoma. Some tumors demonstrate other unique cellular differentiation, such as sebaceous adenoma/carcinoma, lymphadenoma, and mucoepidermoid carcinoma. Immunohistochemistry can be very helpful to determine the cellular differentiation of some of the more unusual tumors, or in variant morphologies of common tumors. Some tumors, such as salivary duct carcinoma and mammary analogue secretory carcinoma, demonstrate more specific immunohistologic profiles, which facilitate the diagnosis.

The acinar/ductal epithelial cells are positive for keratins (CK7 and CAM 5.2) and epithelial membrane antigen (EMA). They are focally positive or negative for highmolecular-weight keratins (HMWKs; CK5/6 and 34PE12) and negative for p63, myoid markers (smooth muscle myosin heavy chain [SMMHC], smooth muscle actin [SMA], calponin), and CK20 (focal weak expression can be seen in rare salivary gland carcinomas). Myoepithelial cells are usually positive for p63, myoid markers (SMMHC, SMA, calponin), vimentin, S100, and HMWKs (CK5/6, 34[beta]E12), but only show weak expression for CK7 and CAM 5.2 and no expression for EMA. Basal cells are positive for p63 and HMWKs (CK5/6, 34PE12), weakly positive or negative for CK7, CAM 5.2 and myoid markers (SMMHC, SMA, calponin), and negative for CK20, vimentin, S100, and EMA. S100 and vimentin are sensitive, but not specific, markers for myoepithelial cells. An important caveat in using p63 as a marker for myoepithelial or basal cells is that it also stains squamous epithelium (Tables 1 through 3; Figure 1, A through F; and Figure 2, A and B). (2-11)

The SRY-related HMG-box 10 (SOX10) protein is a transcription factor that is critical for formation and differentiation of neural crest cells. (12) SOX10 is a more sensitive and specific marker for melanocytic and schwannian tumors than S100. (13) Recently, Ohtomo et al (14) found SOX10 was expressed in both luminal and abluminal cells of intercalated ducts of normal human major salivary glands.

They identified 2 groups of salivary gland tumors on the basis of SOXIO expression. The tumors with frequent and high SOX10 expression are acinic cell carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma, myoepithelial carcinoma, and pleomorphic adenoma, which presumably show similarities to acini and intercalated ducts. The tumors with no SOX10 expression are salivary duct carcinoma, mucoepidermoid carcinoma, squamous cell carcinoma, oncocytic carcinoma, oncocytoma, and Warthin tumor, which are usually thought to resemble striated and excretory ducts. SOX10 expression was present in both neoplastic myoepithelial cells and neoplastic epithelial cells. SOX10 appears to be a potential marker for acinar and intercalated duct differentiation in the diagnosis of salivary gland tumors (Table 4 and Figure 3).

SELECTED SALIVARY GLAND AND HEAD AND NECK TUMORS

Acinic Cell Carcinoma

Acinic cell carcinoma demonstrates both serous acinar and intercalated ductal epithelial differentiation. The tumor has several growth patterns: solid/lobular, microcystic, papillary-cystic, and follicular. Most acinic cell carcinomas express CK7 and CAM 5.2. However, the tumors with acinar pattern are focally positive or negative for CK7. The normal acinar cells express amylase, but most acinic cell carcinomas are negative for this marker. Rare acinic cell carcinomas may express synaptophysin and mucin (MUC) 3. Acinic cell carcinoma is usually negative for p63 and CK20. (3,15-20)

Discovered on gastrointestinal stromal tumor protein 1 (DOG1), also known as anoctamin-1/ANO1, is a calcium-activated chloride channel protein that was initially identified in gastrointestinal stromal tumor and used as an immunohistochemical marker for this tumor. (21) Chenevert et al (22) studied 158 cases of various salivary gland tumors and normal salivary gland tissue for DOG1 expression. DOG1 expression was seen in normal serous acini (apical membranous staining pattern), mucous acini (apical membranous staining pattern), and distal intercalated ducts (apical staining). No DOG1 expression was seen in the myoepithelial cell, striated ducts, or excretory ducts. All 28 acinic cell carcinomas were positive for DOG1 with predominantly apical/luminal membranous staining and scattered foci of cytoplasmic and complete membranous staining, 93% with diffuse (>50%) staining. Most ductal tumors were negative for this marker, but 33% (2 of 6) of mammary analogue secretory carcinomas and 31% (5 of 16) of pleomorphic low-grade adenocarcinomas showed DOG1 immunoreactivity, most of them with focally weak staining. No DOG1 immunoreactivity was seen in salivary duct carcinomas, oncocytomas/oncocytic carcinomas, and myoepitheliomas in the biphasic tumor; 75% (18 of 24 cases) of adenoid cystic carcinomas and 53% (8 of 15 cases) of epithelial-myoepithelial carcinomas were positive, often showing a distinctive combined apical ductal and membranous/cytoplasmic myoepithelial staining profile. Although only occasional focal staining was seen, there were not enough cases to confirm the expression of DOG1 in Warthin tumors, low-grade cribriform cystadenocarcinomas, adenosquamous carcinoma, and sebaceous lymphadenoma. The authors proposed that diffuse and intense DOG1 immunopositivity can be used in conjunction with the periodic acid-Schiff reaction after diastase treatment to distinguish acinic cell carcinomas from morphologic mimics, particularly mammary analogue secretory carcinoma (Figure 4).

Adenoid Cystic Carcinoma

Adenoid cystic carcinoma is a malignant biphasic epithelial tumor composed of modified myoepithelial and ductal cells. Typically, patients with this tumor have a poor long-term prognosis. The tumor can have cribriform, tubular, and solid patterns; frequently, there are mixed growth patterns within the same lesion. Adenoid cystic carcinoma expresses both ductal and myoepithelial/basal cell markers, such as CK7, CAM 5.2, calponin, SMA, SMMHC, p63, SOX10, and S100. (14,23-25)

Most adenoid cystic carcinomas showed strong and diffuse expression of c-KIT, but studies have not identified c-KIT mutations in these tumors (Figure 5). (26-32) c-KIT expression is predominantly located in the inner ductal cells of the tubular and cribriform patterns and was homogeneously expressed in the solid form. (31) This unique immunophenotype is useful in differentiating adenoid cystic carcinoma from some of its mimics. Some salivary gland tumors may show expression of c-KIT, such as basal cell adenocarcinoma, lymphoepithelial carcinoma, myoepithelial carcinoma, and basaloid squamous carcinoma. (26,28,32) Tumors that only rarely expressed c-KIT include pleomorphic adenoma, sebaceous carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma, basal cell carcinoma, oncocytoma, and Warthin tumor. (26) The expression of c-KIT in polymorphous low-grade adenocarcinoma is controversial. While some researchers reported that polymorphous low-grade adenocarcinoma rarely expressed c-KIT or had low expression of c-KIT, others have reported frequent expression of c-KIT in polymorphous low-grade adenocarcinoma. (24,32,33) Further study is necessary to compare the expression of c-KIT in these 2 tumors.

Adenoid cystic carcinomas with high-grade transformation showed elevated Ki-67 and p53 labeling indices in the high-grade components. Overexpression of Ki-67 and p53 was associated with poor prognosis in the patients with adenoid cystic carcinoma. (34-39) Also, these tumors lose the myoepithelial cell component and show an almost pure epithelial population.

Histone H3 lysine 9 trimethylation (H3K9me3) and acetylated histone H3 at lysine 9 (H3K9ac) are histone modifications that play an important role in the transcription of target genes. Xia et al (40) investigated H3K9me3 and H3K9ac expression in 66 cases of adenoid cystic carcinoma. They found that high levels of H3K9me3 expression was associated with solid pattern, higher incidence of distal metastasis, poorer disease-free survival rates and overall survival rates, while low H3K9Ac expression was associated with poor overall survival rates. High levels of H3K9me3 expression and solid pattern tumors were independent prognostic factors that significantly influenced overall survival. H3K9me3 expression was the only independent predictor of disease-free survival.

A recurrent t(6; 9)(q22-23; p23-24) translocation was identified in adenoid cystic carcinoma. (41) This translocation leads to the fusion of MYB and NFIB and the deregulation of the expression of Myb. (42) A balanced translocation between MYB and NFIB was present in 28% to 49% of adenoid cystic carcinomas but was not identified in other salivary gland tumors or nonsalivary gland neoplasms. (43,44) Myb expression was found in 55% to 70% of adenoid cystic carcinomas, even in 46% to 61% of tumors without translocation. (43-45) Myb expression was mainly located in the peripheral myoepithelial cells and was not identified in ductal cells of either the tubular or cribriform patterns. (43,44) Myb expression was found predominantly in the cribriform (50%) and the tubular patterns (61%). Only 12% of the solid form expressed Myb. Myb expression was not detected in nontumoral salivary gland parenchyma. (45) Strong Myb expression was seen in most of Myb-positive adenoid cystic carcinoma. Focal weak Myb expression was identified in other tested salivary gland tumors, including myoepithelial carcinoma, polymorphous low-grade adenocarcinoma, myoepithelioma, pleomorphic adenoma, and mucoepidermoid carcinoma. No Myb expression was seen in basal cell adenoma, oncocytoma, adenosquamous carcinoma, acinic cell carcinoma, and salivary duct carcinoma. A subset of breast carcinoma, seminoma, colorectal carcinoma, and thymoma showed strong Myb expression. (44) Myb appears to be a valuable marker for differentiating a subset of adenoid cystic carcinomas from other salivary gland tumors.

Mammary Analogue Secretory Carcinoma

Mammary analogue secretory carcinoma is a recently categorized salivary gland tumor that is histologically, immunohistochemically, and genetically similar to secretory carcinoma of the breast. (46) The tumor has a t(12; 15)(p13; q25) ETV6-NTRK3 translocation that is also present in breast secretory carcinoma. The tumor has a variety of growth patterns, including lobular, macrocystic, microcystic, papillary, cribriform, tubular, and solid microcystic. The tumor cells demonstrate low-grade nuclei and multivacuolated to eosinophilic granular cytoplasm. Historically, it was most often diagnosed as zymogen-poor acinic cell carcinoma and (cyst) adenocarcinoma and occasionally as mucin-producing signet ring adenocarcinoma or mucoepidermoid carcinoma. (47,48) The tumor expresses S100, mammaglobin, CK7, CK8, CK18, CK19, 34[beta]E12, EMA, gross cystic disease fluid protein 15 (GCDFP-15), GATA3, signal transducer and activator of transcription 5a (STAT5a), MUC1, MUC4, and vimentin (Figure 6, A and B). Basal cell/myoepithelial cell markers, such as p63, calponin, SMA, and CK5/6, usually do not show expression in the tumor. (46,49-52) However, the peripheral layer of residual basal cells surrounding the tumor nests could be highlighted by p63 staining. (47,49) The tumor is negative for androgen receptor (AR), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). The MIB-1 indices range between 5% and 28%. (46)

Compared to mammary analogue secretory carcinoma, acinic cell carcinoma rarely expresses mammaglobin, CK8, and CK19. Only a small percentage of acinic cell carcinomas express S100, vimentin, GCDFP-15. No expression of MUC4 was present in acinic cell carcinoma. (46)

Besides acinic cell carcinoma, the other entity occasionally considered in the differential diagnosis is adenoid cystic carcinoma. However, adenoid cystic carcinoma is rarely positive for mammaglobin, S100, vimentin, CK8, CK19, and GCDFP-15. Mammary analogue secretory carcinoma can be differentiated from mucoepidermoid carcinoma by its expression of S100 and lack of expression of p63. (50,51)

Although coexpression of both mammaglobin and S100 protein is characteristic of mammary analogue secretory carcinoma, polymorphous low-grade adenocarcinomas (60%) and adenoid cystic carcinomas (13.3%) showed significant coexpression of both markers without evidence of ETV6-NTRK3 fusion. (50) Polymorphous low-grade adenocarcinomas and adenoid cystic carcinomas were positive for p63 and negative for GCDFP-15. (25,53) In difficult cases, molecular testing for ETV6-NTRK3 fusion would be helpful for the differential diagnosis. (46)

Mucoepidermoid Carcinoma

Mucoepidermoid carcinoma is a malignant epithelial neoplasm composed of mucous, epidermoid, intermediate, columnar, clear, and oncocytic cells. It is usually positive for CK5, CK6, CK7, CK8, CK14, CK18, CK19, EMA, carcinoembryonic antigen (CEA), and p63 and is negative for CK20, SMA, muscle specific actin (MSA), and S100. However, focal expression of S100, c-KIT, glial fibrillary acidic protein (GFAP), and vimentin can be seen in some tumors (Figure 7, A and B). (20,54-59)

p63 is a useful marker to differentiate acinic cell carcinoma from mucoepidermoid carcinoma. Sams et al (20) compared p63 expression among 31 cases of acinic cell carcinomas and 24 cases of mucoepidermoid carcinomas. They found that all acinic cell carcinomas were negative for p63, while all mucoepidermoid carcinomas were strongly positive for p63. p63 immunohistochemical expression pattern can be helpful in distinguishing low-grade mucoepidermoid carcinoma from mucous retention cysts and papillary cystadenoma of the salivary glands. Fonseca et al (58) found that p63 immunostaining in mucous retention cysts and papillary cystadenomas was limited to the basal layers of the cystic spaces, whereas in low-grade mucoepidermoid carcinomas, positive staining was also found diffusely in the suprabasal layers of the epidermoid component of the tumor. Oncocytic mucoepidermoid carcinoma can also be differentiated from oncocytoma and oncocytic carcinoma by p63 staining pattern. It has been reported that in oncocytic mucoepidermoid carcinomas, more than 50% of the cells throughout the tumor nests were positive for p63, while only scant peripheral cells of the tumor nests in oncocytoma and oncocytic carcinoma were positive for p63. (59)

Myoepithelial Carcinoma

Myoepithelial carcinoma is a malignant tumor of the salivary glands, with tumor cells displaying exclusively myoepithelial differentiation. The tumor cells can be quite diverse, including spindled, stellate, epithelioid, plasmacytoid, or clear cells. They can resemble sarcoma, melanoma, or other tumors. Immunoreactivity for both keratins and at least 1 myoepithelial marker is required for the diagnosis of myoepithelial carcinoma. (60) Myoepithelial carcinomas frequently express vimentin (100%), calponin (75%-100%), S100 (82%-100%), CK AE1/3 (90%-100%), 34[beta]E12 (92%), CAM 5.2 (89%), pancytokeratin (74%), and EMA (21%-100%); less frequently express caldesmon (50%), SMA (35%-50%), MSA (31%), GAFP (31%-50%), SMMHC (30%), p63 (28%), EMA (27%), and Ki-67 (labeling index, 4%-65%); occasionally express CD117 (6%) and desmin (10%); and do not express CEA. (61-64) Calponin appears to be the most sensitive and specific marker to identify myoepithelial differentiation for myoepithelial carcinoma. A panel of multiple markers, including CK AE1/3, CAM 5.2, CK5/6, calponin, SMA, S100, and vimentin, can be helpful to make an accurate diagnosis.

Polymorphous Low-Grade Adenocarcinoma

Polymorphous low-grade adenocarcinoma is a low-grade malignant epithelial carcinoma almost exclusively arising in minor salivary glands with bland cytologic features. This tumor typically has diverse growth patterns, including lobular, papillary or papillary-cystic, cribriform, trabecular, and ductal or tubular areas. The tumor frequently expresses CK AE1/3, CAM 5.2, 34[beta]E12, EMA, p53, p63, vimentin, bcl-2, S100, and it infrequently expresses SMA and GFAP. (65-69) Carcinoembryonic antigen immunoreactivity is present in up to 54% of tumors. Polymorphous low-grade adenocarcinoma has overlapping histologic features with pleomorphic adenoma/canalicular adenoma and adenoid cystic carcinoma. In practice, it is sometimes difficult to distinguish polymorphous low-grade adenocarcinoma from these tumors, especially in small biopsy specimens. Most pleomorphic adenomas show strong GFAP expression, while only rare polymorphous low-grade adenocarcinomas show faint patchy reactivity for GFAP. (65-69) Curran et al (70) reported that 96% of canalicular adenomas demonstrated weak to strong cytoplasmic staining for GFAP, which was confined to a row of cells at the tumor/connective interface. All pleomorphic adenomas demonstrated weak to strong diffuse cytoplasmic staining for GFAP in the ductal and myoepithelial cells, while 2 cases also showed a weakly staining linear row of immunoreactive cells at the tumor/connective tissue. All polymorphous low-grade adenocarcinomas showed little or no intralesional reactivity and no peripheral linear immunoreactivity for GFAP. GFAP can be helpful to distinguish pleomorphic low-grade adenocarcinoma from pleomorphic adenoma/canalicular adenoma (Table 5).

Salivary Duct Carcinoma

Salivary duct carcinoma is an aggressive malignant epithelial tumor arising from intralobular and interlobular excretory ducts. It resembles high-grade breast ductal carcinoma and demonstrates ductal, papillary, solid, and cribriform with comedo necrosis growth patterns.

Salivary duct carcinoma usually expresses AR, GCDFP-15, CK AE1/3, CK7, 34[beta]E12, CEA, and EMA (Figure 8, A through C). Occasionally, it can be positive for ER, PR, and S100. (71-78) The Ki-67 expression markedly increases and the indices are higher than 25%. (73,75,77) Androgen receptor is expressed significantly more often in salivary duct carcinomas of men than in salivary duct carcinomas of women. (79) The immunophenotype [AR.sup.+]/[ER.sup.-]/[PR.sup.-]/[GCDFP.sup.+] is characteristic of salivary duct carcinoma, but it does not completely exclude metastasis from the breast, which might also be [AR.sup.+] and ER--/PR-- in a lesser proportion of cases. (74,80) GATA3, a new marker for breast carcinoma, was detected in all salivary duct carcinomas. (52)

More than 80% of salivary duct carcinomas show HER2/ neu and p53 overexpression, which was correlated to poor prognosis. (77,81-83) However, tumors with HER2/neu expression may respond to trastuzumab-based therapy. (84,85)

Prostatic acid phosphatase and prostate-specific antigen expression can rarely be detected in salivary duct carcinomas from men and women. (86,87) In men with unknown prostatic acid phosphatase-positive and prostate-specific antigen-positive metastatic carcinoma, salivary duct carcinoma should be included in the differential diagnosis in addition to prostatic adenocarcinoma. Expression of CK7 and HMWKs support the diagnosis of salivary duct carcinoma.

Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma

Pleomorphic adenoma is a benign epithelial neoplasm demonstrating both epithelial and modified myoepithelial differentiation with diversified histologic features. The tumor expresses CK7, CK14, CEA, SMA, MSA, SMMHC, calponin, p63, S100, vimentin, Wilms tumor 1 (WT1), and GFAP. (3,8,10,11,71,88-91)

Pleomorphic adenoma gene 1 (PLAG1) is a protooncogene that is activated by recurrent chromosome rearrangements in pleomorphic adenoma, resulting in PLAG1 protein overexpression. (92-94) Rotellini et al (95) examined 101 benign and malignant salivary gland tumors, including 36 pleomorphic adenomas, 8 myoepitheliomas, 3 basal cell adenomas, and 1 canalicular adenoma among the benign tumors; 16 mucoepidermoid carcinomas, 10 adenoid cystic carcinomas, 8 acinic cell carcinomas, 8 polymorphous low-grade adenocarcinomas, 7 salivary duct carcinomas, and 4 epithelial-myoepithelial carcinomas among malignant tumors. They found that PLAG1 protein showed diffuse positivity in 94.4% of pleomorphic adenomas and weak positivity in all myoepitheliomas. Among malignant tumors, only 2 polymorphous lowgrade adenocarcinomas and 1 salivary duct carcinoma ex pleomorphic adenoma were positive; other tumors were negative. The authors concluded that PLAG1 protein is a sensitive and specific marker for pleomorphic adenoma and can be useful to differentiate pleomorphic adenoma from adenoid cystic carcinoma, mucoepidermoid carcinoma, epithelial-myoepithelial carcinoma, and acinic cell carcinoma.

Carcinoma ex pleomorphic adenoma is a malignant epithelial neoplasm arising from benign pleomorphic adenoma. Bahrami et al (96) studied PLAG1 expression by immunostaining and PLAG1 gene rearrangement by fluorescence in situ hybridization (FISH) in 22 carcinoma ex pleomorphic adenomas along with 39 cases representing various benign and malignant salivary gland neoplasms: adenocarcinomas, not otherwise specified (4 cases); mucoepidermoid carcinomas (8 cases); adenoid cystic carcinomas (7 cases); salivary duct carcinomas (4 cases); epithelial-myoepithelial carcinomas (2 cases); polymorphous low-grade adenocarcinoma (1 case); myoepithelial carcinoma (1 case); adenoid cystic carcinoma (1 case); basaloid carcinoma (1 case); pleomorphic adenomas (5 cases); basal cell adenomas (4 cases); and low-grade salivary gland neoplasm, not otherwise specified (1 case). They found that all 5 pleomorphic adenomas were positive for PLAG1 ([2.sup.+] to [3.sup.+]); 17 of 22 carcinomas ex pleomorphic adenoma were positive for PLAG1 ([1.sup.+] to [3.sup.+]), while 5 of 22 carcinomas ex pleomorphic adenomas scored as rare (1%-4% positive cells) or negative. All other tumors scored as rare (1%-4% positive cells) or negative. Fluorescence in situ hybridization study showed that 12 of 19 carcinomas ex pleomorphic adenoma (63%) were positive for gene rearrangement, 2 showed only a trisomy/polysomy profile, and 5 had a normal pattern. One FISH-positive tumor showed amplification of PLAG1. One of 3 cases analyzed for high-mobility-group AT-hook 2 gene (HMGA2) by FISH was positive for gene rearrangement. The authors suggested that a diffuse and unequivocal expression for PLAG1 in a carcinoma is a strong indication for the diagnosis of carcinoma ex pleomorphic adenoma in the proper clinicopathologic setting. Immunostaining for PLAG1 protein and FISH for PLAG1, particularly in combination, may be helpful ancillary studies for carcinoma ex pleomorphic adenoma.

Nuclear Protein in Testis Midline Carcinomas

Nuclear protein in testis (NUT) midline carcinomas are rare, aggressive malignant epithelial tumors arising from midline structures, including upper aerodigestive tract, thymus, mediastinum, lung, and bladder. (97-100) Approximately half of these tumors occur in the head and neck regions. The NUT midline carcinomas affect patients from childhood to old age, though they many occur in children and young adults. The tumors present as poorly or undifferentiated carcinomas that frequently contain aberrant and abrupt squamous differentiation. These tumors may be mistaken for poorly differentiated or undifferentiated carcinoma, squamous cell carcinoma, Ewing sarcoma, sinonasal undifferentiated carcinoma, thymic carcinoma, or neuroblastoma. It is important to recognize this type of malignancy because the patients with NUT midline carcinomas have much poorer prognosis than those with nonNUT midline carcinomas. The NUT midline carcinomas have characteristic chromosomal rearrangements of the NUT gene at 15q14. The most common translocation involving the NUT gene is the t(15; 19)(q14; p13.1), resulting in BRD4-NUT fusions. (100)

The NUT midline carcinomas are positive for CK7, p40, p63, and EMA and are negative or only focally positive for CK20. Approximately one-third of NUT midline carcinomas are positive for CD34. Rare tumors may show focal weak immunoreactivity for synaptophysin, chromogranin, and S100. (99,101,102)

The diagnosis of NUT midline carcinomas can be made by demonstration of NUT rearrangement by FISH or by demonstration of a BRD4-NUT fusion transcript by reverse transcription-polymerase chain reaction (PCR). (103) Recently, Haack et al (104) studied NUT expression in a panel of 1068 tissues, including 30 FISH-positive NUT midline carcinomas and 876 other carcinomas, by using C52, a rabbit monoclonal antibody against a recombinant NUT polypeptide (Cell Signaling Technologies, Inc, Danvers, Massachusetts). They found that the C52 immunostain achieved a sensitivity of 87% and a specificity of 100% in NUT midline carcinomas. Some germ cell tumors, including 6% of seminomas, 8.6% of embryonal carcinomas, and 64% of dysgerminomas, showed weak, focal nuclear staining. Among normal tissues, weak cytoplasmic staining was seen in hepatocytes and rare renal tubular cells. No other carcinomas showed immunoreactivity to C52. The study confirmed that C52 immunostain is a new sensitive and highly specific marker for NUT midline carcinomas. Owing to possible false-negative NUT expression by immunostaining, the authors suggested that FISH for NUT rearrangements should be performed when C52 immunostaining is negative and NUT midline carcinoma remains highly likely in the differential diagnosis (Table 6).

Human Papillomavirus-Positive Carcinomas of Oropharynx and Oral Cavity

Human papillomavirus (HPV), predominantly HPV 16, infection has been identified in a unique subset of patients with head and neck squamous cell carcinomas especially carcinomas of oropharynx and base of tongue. There is extensive evidence to support a causal role of HPV in oral carcinomas. (105-108) The prevalence of HPV infection in oropharyngeal carcinoma has increased significantly over time, from 40.5% before 2000 to 72.2% between 2005 and 2009, while the HPV prevalence in nonoropharyngeal carcinoma has not increased (18.9%-25.1%). (109,110) The patients with HPV-positive head and neck squamous cell carcinomas are younger than patients with HPV-negative tumors. More often these tumors are seen in nonsmokers and nondrinkers, are less likely to harbor p53 mutations, and often have a favorable prognosis. (111-114) It is important to identify the HPV-positive carcinomas of oropharynx and oral cavity owing to their unique biological and clinical behaviors. Personalized therapy may provide the maximal benefit for patients, depending on their HPV status.

In the HPV-infected tumor cells, the expression of HPV E2 viral transcription/replication factor is disrupted, resulting in dysregulation of expression of viral E6 and E7 oncogenes. The viral E6 and E7 oncoproteins inactivate p53 and retinoblastoma (Rb) proteins, which lead to the overexpression of p16, a cyclin-dependent kinase inhibitor.115-117 Direct detection of HPV messenger RNA by reverse transcription-PCR, and HPV DNA by PCR and FISH, is laborious, expensive, technically challenging, and not available in many laboratories. However, immunohistochemistry is a relatively simple and inexpensive method widely used in most laboratories. p16 overexpression was highly correlated with HPV-positive tumors (detected in up to 98% of HPV-positive carcinomas) (Figure 9). Patients with p16-positive squamous cell carcinomas of oropharynx and oral cavity showed improved local tumor control, improved disease-free survival, and better overall survival, compared to patients with p16-negative squamous cell carcinomas. (118-129) p16 immunostain was considered a very sensitive surrogate biomarker for HPV infection, although p16 positivity is not 100% specific for HPV infection. Lewis et al (127) analyzed p16 overexpression and HPV status in 239 cases of oropharyngeal carcinoma. They found 78% of cases were positive for p16; of these, 74% were positive for HPV by in situ hybridization (ISH). In 45 p16-positive, HPV ISH-negative cases, 19 were positive for HPV by PCR. In the p16-positive cohort, there was no difference in survival between HPV-ISH positive and HPV ISH-negative cases. Comparing the HPV ISH-positive and HPV ISH- and PCR-negative carcinomas, there was again no difference in survival. p16-positive, HPV-negative carcinomas were associated with significantly better survival than p16-negative carcinomas. The authors concluded that p16 immunostaining is the best test for risk stratification in oropharyngeal squamous cell carcinoma.

The 2011 National Comprehensive Cancer Network guidelines (130) recommended p16 immunostain alone as a valuable prognostic marker for patients with oropharyngeal cancers.

For metastatic squamous cell carcinoma of the cervical lymph nodes of unknown primary, p16 immunostaining as well as HPV tests can be helpful in identifying a hidden oropharyngeal primary tumor. (131-133) El-Mofty et al (131) reported that among 93 cases of head and neck squamous cell carcinoma with cervical lymph node metastasis, 23 cases were positive for HPV by ISH; of these, 22 of 23 were of oropharyngeal origin. Twenty-one HPV-positive oropharyngeal carcinomas were nonkeratinizing and strongly and diffusely positive for p16 immunostain. Begum et al (133) found that in 68 cases of head and neck squamous cell carcinoma with cervical lymph node metastasis, HPV 16 was detected by ISH in 22 of 31 metastases from the oropharynx (71%) but in none of the 37 metastases from other sites (0%). p16 expression was detected in 24 of 31 metastases from the oropharynx, and only 1 of 37 nonoropharyngeal carcinomas was p16 positive.

CONCLUSIONS

In summary, immunohistochemistry plays an important role in the diagnosis of certain salivary gland and head and neck tumors. The keratin markers (CK7, CAM 5.2, CK5/6, and 34bE12) and myoid/basal cell markers (calponin, SMA, SMMHC, and p63) can be used to identify the cellular differentiation of most salivary gland tumors. Other markers, including c-KIT, GFAP, Myb, AR, GCDFP-15, mammaglobin, SOX10, DOG1, and PLGA1, are useful in the differential diagnosis of salivary gland tumors. The NUT midline carcinomas can be detected by the highly specific and sensitive marker C52. H3K9me3, H3K9ac, MIB-1, and p53 maybe used to identify some aggressive tumors. Finally, p16, a sensitive surrogate marker for HPV infection, can provide prognostic information for HPV-positive oropharyngeal carcinomas and is helpful for identifying oropharyngeal primary tumor of metastatic cervical lymph node.

Please Note: Illustration(s) are not available due to copyright restrictions.

References

(1.) Eveson JW, Auclair P, Gnepp DR, et al. Tumours of the salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005:210. World Health Organization Classification of Tumours; vol 9.

(2.) Nikitakis NG, Tosios KI, Papanikolaou VS, et al. Immunohistochemical expression of cytokeratins 7 and 20 in malignant salivary gland tumors. Mod Pathol. 2004; 17(4):407-415.

(3.) Meer S, Altini M. CK7-+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology. 2007; 51(1):26-32.

(4.) de Araujo VC, de Sousa SO. Expression of different keratins in salivary gland tumours. Eur J Cancer B Oral Oncol. 1996; 32B(1):14-18.

(5.) Tatemoto Y, Kumasa S, Watanabe Y, et al. Epithelial membrane antigen as a marker of human salivary gland acinar and ductal cell function. Acta Histochem. 1987; 82(2):219-226.

(6.) Foschini MP, Scarpellini F, Gown AM, et al. Differential expression of myoepithelial markers in salivary, sweat and mammary glands. Int J Surg Pathol. 2000; 8(1):29-37.

(7.) Seethala RR, LiVolsi VA, Zhang PJ, et al. Comparison of p63 and p73 expression in benign and malignant salivary gland lesions. Head Neck. 2005; 27(8):696-702.

(8.) Bilal H, Handra-Luca A, Bertrand JC, et al. p63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. J Histochem Cytochem. 2003; 51(2):133-139.

(9.) Prasad AR, Savera AT, Gown AM, et al. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med. 1999; 123(9):801-806.

(10.) Savera AT, Gown AM, Zarbo RJ. Immunolocalization of three novel smooth muscle-specific proteins in salivary gland pleomorphic adenoma: assessment of the morphogenetic role of myoepithelium. Mod Pathol. 1997; 10(11):1093-1100.

(11.) Nakazato Y, Ishida Y, Takahashi K, et al. Immunohistochemical distribution of S-100 protein and glial fibrillary acidic protein in normal and neoplastic salivary glands. Virchows Arch A Pathol Anat Histopathol. 1985; 405(3):299-310.

(12.) Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays. 2006; 28(8):788-798.

(13.) Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008; 32(9):1291-1298.

(14.) Ohtomo R, Mori T, Shibata S, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. 2013; 26(8):1041-1050.

(15.) Childers EL, Ellis GL, Auclair PL. An immunohistochemical analysis of anti-amylase antibody reactivity in acinic cell adenocarcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 81(6):691-694.

(16.) Morley DJ, Hodes ME. Amylase expression in human parotid neoplasms: evidence by in situ hybridization for lack of transcription of the amylase gene. J Histochem Cytochem. 1988; 36(5):487-491.

(17.) Crivelini MM, de Sousa SO, de Araujo VC. Immunohistochemical study of acinic cell carcinoma of minor salivary gland. Oral Oncol. 1997; 33(3):204-208.

(18.) Warner TF, Seo IS, Azen EA, et al. Immunocytochemistry of acinic cell carcinomas and mixed tumors of salivary glands. Cancer. 1985; 56(9):2221-2227.

(19.) Schwarz S, Zenk J, Muller M, et al. The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology. 2012; 61(3):395-408.

(20.) Sams RN, Gnepp DR. P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. Head Neck Pathol. 2013; 7(1):64-68.

(21.) Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009; 33(9):1401-1408.

(22.) Chenevert J, Duvvuri U, Chiosea S, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012; 25(7): 919-929.

(23.) Vargas H, Sudilovsky D, Kaplan MJ, et al. Mixed tumor, polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma: pathogenic implications and differential diagnosis by Ki-67 (MIB1), BCL2, and S-100 immunohistochemistry. Appl Immunohistochem Mol Morphol. 1997; 5(1):8-16.

(24.) Beltran D, Faquin WC, Gallagher G, et al. Selective immunohistochemical comparison of polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma. J Oral Maxillofac Surg. 2006; 64(3):415-423.

(25.) Prasad ML, Barbacioru CC, Rawal YB, et al. Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol. 2008; 21(2):105-114.

(26.) Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol. 2003; 16(12):1224-1231.

(27.) Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999; 12(10):956-960.

(28.) Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000; 154(1):107-111.

(29.) Freier K, Flechtenmacher C, Walch A, et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol. 2005; 41(9):934-939.

(30.) Vila L, Liu H, Al-Quran SZ, et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol. 2009; 22(10):1296-1302.

(31.) Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol. 2002; 15(7):687-691.

(32.) Andreadis D, Epivatianos A, Poulopoulos A, et al. Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol. 2006; 42(1):57-65.

(33.) Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95(5):586-593.

(34.) Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and review of the literature. Am J Surg Pathol. 2007; 31(11):1683-1694.

(35.) Triantafillidou K, Dimitrakopoulos J, Iordanidis F, et al. Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg. 2006; 64(7):1114-1120.

(36.) Norberg-Spaak L, Dardick I, Ledin T. Adenoid cystic carcinoma: use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head Neck. 2000; 22(5):489-497.

(37.) da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, et al. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol. 2006; 42(2):139-146.

(38.) Yamamoto Y, Wistuba II, Kishimoto Y, et al. DNA analysis at p53 locus in adenoid cystic carcinoma: comparison of molecular study and p53 immunostaining. Pathol Int. 1998; 48(4):273-280.

(39.) Nagao T, Gaffey TA, Serizawa H, et al. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod Pathol. 2003; 16(12):1265-1272.

(40.) Xia R, Zhou R, Tian Z, et al. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med. 2013; 137(12):1761-1769.

(41.) Nordkvist A, Mark J, Gustafsson H, et al. Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands. Genes Chromosomes Cancer. 1994; 10(2):115-121.

(42.) Persson M, Andreen Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009; 106(44):18740-18744.

(43.) Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010; 16(19):4722-4731.

(44.) West RB, Kong C, Clarke N, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011; 35(1):92-99.

(45.) Bell D, Roberts D, Karpowicz M, et al. Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther. 2011; 12(7):569-573.

(46.) Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010; 34(5):599-608.

(47.) Chiosea SI, Griffith C, Assaad A, et al. The profile of acinic cell carcinoma after recognition of mammary analogue secretory carcinoma. Am J Surg Pathol. 2012; 36(3):343-350.

(48.) Chiosea SI, Griffith C, Assaad A, et al. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012; 61(3):387-394.

(49.) Connor A, Perez-Ordonez B, Shago M, et al. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012; 36(1):27-34.

(50.) Patel KR, Solomon IH, El-Mofty SK, et al. Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma. Hum Pathol. 2013; 44(11):2501-2508.

(51.) Bishop JA, Yonescu R, Batista D, et al. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol. 2013; 44(10):1982-1988.

(52.) Schwartz LE, Begum S, Westra WH, Bishop JA. GATA3 immunohistochemical expression in salivary gland neoplasms. Head Neck Pathol. 2013; 7(4): 311-315.

(53.) Swanson PE, Pettinato G, Lillemoe TJ, et al. Gross cystic disease fluid protein-15 in salivary gland tumors. Arch Pathol Lab Med. 1991; 115(2):158-163.

(54.) Azevedo RS, de Almeida OP, Kowalski LP, et al. Comparative cytokeratin expression in the different cell types of salivary gland mucoepidermoid carcinoma. Head Neck Pathol. 2008; 2(4):257-264.

(55.) Regezi JA, Zarbo RJ, Batsakis JG. Immunoprofile of mucoepidermoid carcinomas of minor salivary glands. Oral Surg Oral Med Oral Pathol. 1991; 71(2):189-192.

(56.) Wolfish EB, Nelson BL, Thompson LD. Sinonasal tract mucoepidermoid carcinoma: a clinicopathologic and immunophenotypic study of 19 cases combined with a comprehensive review of the literature. Head Neck Pathol. 2012; 6(2):191-207.

(57.) Loyola AM, de Sousa SO, Araujo NS, et al. Study of minor salivary gland mucoepidermoid carcinoma differentiation based on immunohistochemical expression of cytokeratins, vimentin and muscle-specific actin. Oral Oncol. 1998; 34(2):112-118.

(58.) Fonseca FP, de Andrade BA, Lopes MA, et al. p63 expression in papillary cystadenoma and mucoepidermoid carcinoma of minor salivary glands. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115(1):79-86.

(59.) Weinreb I, Seethala RR, Perez-Ordonez B, et al. Oncocytic mucoepidermoid carcinoma: clinicopathologic description in a series of 12 cases. Am J Surg Pathol. 2009; 33(3):409-416.

(60.) Skalova A, Jakel KT. Myoepithelial carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005:240. World Health Organization Classification of Tumours; vol 9.

(61.) Kane SV, Bagwan IN. Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 51 cases in a tertiary cancer center. Arch Otolaryngol Head Neck Surg. 2010; 136(7):702-712.

(62.) Hungermann D, Roeser K, Buerger H, et al. Relative paucity of gross genetic alterations in myoepitheliomas and myoepithelial carcinomas of salivary glands. J Pathol. 2002; 198(4):487-494.

(63.) Nagao T, Sugano I, Ishida Y, et al. Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases. Cancer. 1998; 83(7):1292-1299.

(64.) Savera AT, Sloman A, Huvos AG, et al. Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol. 2000; 24(6):761-774.

(65.) Perez-Ordonez B, Linkov I, Huvos AG. Polymorphous low-grade adenocarcinoma of minor salivary glands: a study of 17 cases with emphasis on cell differentiation. Histopathology. 1998; 32(6):521-529.

(66.) Castle JT, Thompson LD, Frommelt RA, et al. Polymorphous low-grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer. 1999; 86(2): 207-219.

(67.) Edwards PC, Bhuiya T, Kelsch RD. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(5):613-619.

(68.) Gnepp DR, el-Mofty S. Polymorphous low grade adenocarcinoma: glial fibrillary acidic protein staining in the differential diagnosis with cellular mixed tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83(6):691-695.

(69.) Curran AE, White DK, Damm DD, et al. Polymorphous low-grade adenocarcinoma versus pleomorphic adenoma of minor salivary glands: resolution of a diagnostic dilemma by immunohistochemical analysis with glial fibrillary acidic protein. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91(2):194-199.

(70.) Curran AE, Allen CM, Beck FM, et al. Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands. Head Neck Pathol. 2007; 1(1):27-32.

(71.) Lewis JE, McKinney BC, Weiland LH, et al. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996; 77(2):223-230.

(72.) Barnes L, Rao U, Contis L, et al. Salivary duct carcinoma, part II: immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994; 78(1):74-80.

(73.) Nagao T, Gaffey TA, Visscher DW, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004; 28(3):319-326.

(74.) Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998; 11(11):1033-1038.

(75.) Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009; 45(11):986-990.

(76.) Nagao T, Gaffey TA, Serizawa H, et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol. 2004; 122(2):222-231.

(77.) Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005; 103(12): 2526-2533.

(78.) Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001; 127(9):1075-1079.

(79.) Williams MD, Roberts D, Blumenschein GR Jr, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007; 31(11):1645-1652.

(80.) Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993; 170(1):31-35.

(81.) Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology. 2011; 43(5):459-464.

(82.) Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2007; 133(10):1031-1036.

(83.) Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004; 10(3): 944-946.

(84.) Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008; 30(5):680-683.

(85.) Nabili V, Tan JW, Bhuta S, et al. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007; 29(10):907-912.

(86.) Chunyang F, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma. Am J Surg Pathol. 2000; 24(4):579-586.

(87.) Hall RE, Clements JA, Birrell SN, et al. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer. 1998; 78(3):360-365.

(88.) Furuse C, Cury PR, de Araujo NS, et al. Application of two different clones of vimentin to the diagnosis of salivary gland tumors. Appl Immunohistochem Mol Morphol. 2006; 14(2):217-219.

(89.) Langman G, Andrews CL, Weissferdt A. WT1 expression in salivary gland pleomorphic adenomas: a reliable marker of the neoplastic myoepithelium. Mod Pathol. 2011; 24(2):168-174.

(90.) Ogawa Y, Toyosawa S, Ishida T, et al. Keratin 14 immunoreactive cells in pleomorphic adenomas and adenoid cystic carcinomas of salivary glands. Virchows Arch. 2000; 437(1):58-68.

(91.) Kas K, Voz ML, Roijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3; 8)(p21; q12) translocations. Nat Genet. 1997; 15(2):170-174.

(92.) Voz ML, Astrom AK, Kas K, et al. The recurrent translocation t(5; 8)(p13; q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene. 1998; 16(11):1409-1416.

(93.) Asp J, Persson F, Kost-Alimova M, et al. CHCHD7-PLAG1 and TCEA1-PLAG1 gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas. Genes Chromosomes Cancer. 2006; 45(9):820-828.

(94.) Queimado L, Lopes C, Du F, et al. Pleomorphic adenoma gene 1 is expressed in cultured benign and malignant salivary gland tumor cells. Lab Invest. 1999; 79(5):583-589.

(95.) Rotellini M, Palomba A, Baroni G, et al. Diagnostic utility of PLAG1 immunohistochemical determination in salivary gland tumors [published online ahead of print August 16, 2013]. Appl Immunohistochem Mol Morphol. doi:10. 1097/PAI.0b013e3182936ea7.

(96.) Bahrami A, Dalton JD, Shivakumar B, et al. PLAG1 alteration in carcinoma ex pleomorphic adenoma: immunohistochemical and fluorescence in situ hybridization studies of 22 cases. Head Neck Pathol. 2012; 6(3):328-335.

(97.) French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004; 22(20):4135-4139.

(98.) French CA. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol. 2008; 63(6):492-496.

(99.) Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008; 32(6):828-834.

(100.) Toretsky JA, Jenson J, Sun CC, et al. Translocation (11; 15; 19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol. 2003; 26(3):300-306.

(101.) Tilson MP, Bishop JA. Utility of p40 in the differential diagnosis of small round blue cell tumors of the sinonasal tract [published online ahead of print October 11, 2013]. Head Neck Pathol. doi:10.1007/s12105-013-0496-2.

(102.) Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am I Surg Pathol. 2012; 36(8):1216-1221.

(103.) Engleson J, Soller M, Panagopoulos I, et al. Midline carcinoma with t(15; 19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy. BMC Cancer. 2006; 6:69.

(104.) Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. J Surg Pathol. 2009; 33(7):984-991.

(105.) de Villiers EM, Weidauer H, Otto H, et al. Papillomavirus DNA in human tongue carcinomas. Int J Cancer. 1985; 36(5):575-578.

(106.) Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92(2):709-720.

(107.) Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001; 344(15):1125-1131.

(108.) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: A Review of Human Carcinogens: Biological Agents. Lyon, France: IARC Press; 2011; 100B: 278-280.

(109.) Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013; 35(5):747-755.

(110.) Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26(4):612-619.

(111.) El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101(3): 339-345.

(112.) Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006; 24(36):5630-5636.

(113.) Ringstrom E, Peters E, Hasegawa M, et al. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002; 8(10): 3187-3192.

(114.) Schwartz SR, Yueh B, McDougall JK, et al. HPV infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001; 125(1):1-9.

(115.) Psyrri A, DeFilippis RA, Edwards AP, et al. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res. 2004; 64(9):3079-3086.

(116.) Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6):1129-1136.

(117.) Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78(21):11451-11460.

(118.) Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009; 140(2):228-234.

(119.) Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142-4148.

(120.) Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008; 26(19):3128-3137.

(121.) Rietbergen MM, Brakenhoff RH, Bloemena E, et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials. Ann Oncol. 2013; 24(11): 2740-2745.

(122.) Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 24(5):736-747.

(123.) Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 162(3):747-753.

(124.) Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27(12):1992-1998.

(125.) Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011; 17(19):6262-6271.

(126.) Thavaraj S, Stokes A, Guerra E, et al. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol. 2011; 64(4):308-312.

(127.) Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010; 34(8):1088-1096.

(128.) Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011; 35(9):1343-1350.

(129.) Schlecht NF, Brandwein-Gensler M, Nuovo GJ, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol. 2011; 24(10):1295-1305.

(130.) Pfister DG, Ang KK, Brizel DM, et al. National Comprehensive Cancer Network. Head and neck cancers. J Natl Compr Canc Netw. 2011; 9(6):596-650.

(131.) El-Mofty SK, Zhang MQ, Davila RM. Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma. Head Neck Pathol. 2008; 2(3):163-168.

(132.) Park GC, Lee M, Roh JL, et al. Human papillomavirus and p16 detection in cervical lymph node metastases from an unknown primary tumor. Oral Oncol. 2012; 48(12):1250-1256.

(133.) Begum S, Gillison ML, Ansari-Lari MA, et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003; 9(17):6469-6475.

Shaobo Zhu, MD; Conrad Schuerch, MD; Jennifer Hunt, MD

Accepted for publication May 13, 2014.

From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania (Drs Zhu and Schuerch); and the Department of Pathology, University of Arkansas for Medical Sciences, Little Rock (Dr Hunt).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Shaobo Zhu, MD, Department of Laboratory Medicine, MC 01-31, Geisinger Medical Center, 100 N Academy Ave, Danville, PA 17822 (e-mail: szhu1@geisinger.edu).

Caption: Figure 1. Expression of myoepithelial/basal markers in normal salivary glands. A, Calponin expression in myoepithelial cells of acini. B, Smooth muscle actin expression in myoepithelial cells of acini and intercalated duct. C, Smooth muscle myosin heavy chain expression in myoepithelial cells of acini and intercalated duct. D, Cytokeratin 5/6 expression in myoepithelial cells of acini and basal cells of excretory duct. E, p63 expression in myoepithelial cells of acini and basal cells of excretory duct. F, S100 expression in myoepithelial cells of acini (original magnification X400 [A through F]).

Caption: Figure 2. Keratin expression in normal salivary glands. A, CAM 5.2 expression in acini and ducts. B, Cytokeratin 7 expression in acini and ducts (original magnification X400 [A and B]).

Caption: Figure 3. SOX10 expression in adenoid cystic carcinoma (original magnification X400).

Caption: Figure 4. Discovered on gastrointestinal stromal tumor protein 1 (DOG1) expression in acinic cell carcinoma (original magnification X400).

Caption: Figure 5. c-KIT expression in adenoid cystic carcinoma (original magnification X400).

Caption: Figure 6. A, S100 expression in mammary analogue secretory carcinoma. B, Mammaglobin expression in mammary analogue secretory carcinoma (original magnification X400 [A and B]).

Caption: Figure 7. A, Cytokeratin 5/6 expression in mucoepidermoid carcinoma. B, p63 expression in mucoepidermoid carcinoma (original magnification X400 [A and B]).

Caption: Figure 8. A, Androgen receptor expression in salivary duct carcinoma. B, Gross cystic disease fluid protein 15 (GCDFP-15) expression in salivary duct carcinoma. C, HER2/neu expression in salivary duct carcinoma (original magnifications X400 [A through C]).

Caption: Figure 9. p16 expression in tonsillar squamous cell carcinoma (original magnification X400).
Table 1. Expression of Immunomarkers in Normal Salivary Glands

                     Interlobular/Excretory    Striated
                       Duct Luminal Cells     Duct Cells

Calponin/SMA/SMMHC             -                  -
CK7/CAM 5.2                    +                  +
CK5/6 and 34[beta]E12          -                  -
p63                            -                  -
S100                           -                  -
Vimentin                       -                  -

                        Intercalated           Acinar
                     Duct Luminal Cells   Epithelial Cells

Calponin/SMA/SMMHC           -                   -
CK7/CAM 5.2                  +                 +weak
CK5/6 and 34[beta]E12        -                   -
p63                          -                   -
S100                       + or -                -
Vimentin                     -                   -

                           Basal      Myoepithelial
                           Cells          Cells

Calponin/SMA/SMMHC           -              +
CK7/CAM 5.2              +weak or -       +weak
CK5/6 and 34[beta]E12        +              +
p63                          +              +
S100                         -              +
Vimentin                     -              +

Abbreviations: CK, cytokeratin; SMA, smooth muscle actin; SMMHC,
smooth muscle myosin heavy chain; +, usually more than 70% of cases
are positive; -, usually less than 5% of cases are positive; + or
-, usually more than 50%, but less than 70%, of cases are positive;
-or +, usually less than 50% of cases are positive; +weak, weakly
positive; +weak or -, weakly positive or negative.

Table 2. Markers for Salivary Gland Tumors With Clear Cell
Differentiation

                          EMC         MEC     MC     CCC   ACC

p63                  +, outer layer    +      +       +     -
Calponin/SMA/SMMHC   +, outer layer    -      +       -     -
CK7/CAM 5.2          +, inner layer    -    - or +    +     +
SOX10                      +           -      +      ND     +

                      OC/OCA

p63                  +, basal
Calponin/SMA/SMMHC      -
CK7/CAM 5.2             +
SOX10                   -

Abbreviations: ACC, acinic cell carcinoma; CCC, clear cell
carcinoma; CK, cytokeratin; EMC, epithelial-myoepithelial carcinoma;
MC, myoepithelial carcinoma; MEC, mucoepidermoid carcinoma; ND, no
data; OC/OCA, oncocytoma/oncocytic carcinoma; SMA, smooth muscle
actin; SMMHC, smooth muscle myosin heavy chain; SOX10, SRY-related
HMG-box 10.

Table 3. Markers for Salivary Gland Tumors With Oncocytic
Differentiation

                     MEC        EMC         ACC      OC/OCA       SDC

p63                   +    +, outer layer    -    +, peripheral    -
Calponin/SMA/SMMHC    -    +, outer layer    -          -          -
CK7/CAM 5.2           -    +, inner layer    +          +          +
AR                    -          -           -          -          +
SOX10                 -          +           +          -          -

Abbreviations: ACC, acinic cell carcinoma; AR, androgen receptor;
CK, cytokeratin; EMC, epithelial-myoepithelial carcinoma; MEC,
mucoepidermoid carcinoma; OC/OCA, oncocytoma/oncocytic carcinoma;
SDC, salivary duct carcinoma; SMA, smooth muscle actin; SMMHC,
smooth muscle myosin heavy chain; SOX10, SRY-related HMG-box 10.

Table 4. SOX10 Expression in Salivary Gland Tumors

SOX10-positive tumors
 Acinic cell carcinomas
 Adenoid cystic carcinomas
 Epithelial-myoepithelial carcinomas
 Myoepithelial carcinomas
 Pleomorphic adenomas
SOX10-negative tumors
 Salivary duct carcinomas
 Mucoepidermoid carcinomas
 Squamous cell carcinomas
 Oncocytic carcinomas/oncocytomas
 Warthin tumors

Abbreviation: SOX10, SRY-related HMG-box 10.

Table 5. The Differentiation of Adenoid Cystic Carcinoma,
Polymorphous Low-Grade Adenocarcinoma, and Pleomorphic Adenoma

       c-KIT    Calponin/SMA/SMMHC         CK7          MIB-1

AdCC     +              +            +, luminal cells   >10%
PLGA   - or +     - or +, focal      +, all cells        <5%
PA     - or +           +            +, luminal cells    <5%

        Myb     PLGA1   GFAP

AdCC   + or -     -      -
PLGA     -        -      -
PA       -        +      +

Abbreviations: AdCC, adenoid cystic carcinoma; CK, cytokeratin;
GFAP, glial fibrillary acidic protein; PA, pleomorphic adenoma;
PLGA, polymorphous low-grade adenocarcinoma; SMA, smooth muscle
actin; SMMHC, smooth muscle myosin heavy chain.

Table 6. Differentiation of Nuclear Protein in Testis
(NUC) Midline Carcinomas, Nasopharyngeal
Carcinoma, Small Cell Neuroendocrine Carcinoma,
and Sinonasal Undifferentiated Carcinoma

                 NMC    SNUC    NPC    SCN

EBV               -      -       +      -
NUT (C52)         +      -       -      -
p63               +    - or +    +    - or +
Synaptophysin,    -      -       -      +
  chromogranin

Abbreviations: EBV, Epstein-Barr virus; NMC, NUT midline carcinoma;
NPC, nasopharyngeal carcinoma; SCN, small cell neuroendocrine
carcinoma; SNUC, sinonasal undifferentiated carcinoma.
COPYRIGHT 2015 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Zhu, Shaobo; Schuerch, Conrad; Hunt, Jennifer
Publication:Archives of Pathology & Laboratory Medicine
Date:Jan 1, 2015
Words:9541
Previous Article:Application of Immunohistochemistry in Gastrointestinal and Liver Neoplasms :New Markers and Evolving Practice.
Next Article:An Update on the Application of Newly Described Immunohistochemical Markers in Soft Tissue Pathology.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters